- Patients
- Clinical Research
- Find a clinical trial
- REJOICE-Ovarian01
Ovarian Cancer
REJOICE-Ovarian01
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Trial overview
Medical oncology
Ovarian cancer
ll/lll
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
St Andrew's Precinct (Oncology)
Level 1, 337 South Terrace, Adelaide, SA, 5000, Australia
Medical Oncologist
Dr Ayesha Salim
MBBS FRACP
Elizabeth Vale at Calvary Central Districts Hospital (Oncology) +1

Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.